Source comparison
BPC-157 Research Sleep Latency: Administration Timing vs Sleep Architecture Comparison
Early Active Phase (morning in humans, evening in nocturnal rodents) +2–5% Minimal No significant change Peptide clears before circadian sleep pressure peaks Mid Active Phase (afternoon) +8–14% +10–18 minutes −6–9% reduction Moderate overlap with pre-sleep tra
This comparison does not assign a generated winner or score.
- Early Active Phase (morning in humans, evening in nocturnal rodents)
- +2–5%
- Minimal
- No significant change
- Peptide clears before circadian sleep pressure peaks
- Mid Active Phase (afternoon)
- +8–14%
- +10–18 minutes
- −6–9% reduction
- Moderate overlap with pre-sleep transition window
- Late Active Phase (evening in humans, early morning in nocturnal rodents)
- +18–26%
- +22–35 minutes
- −12–18% reduction
- Peak interference with GABAergic sleep initiation
- During Rest Phase (nighttime in humans, daytime in nocturnal rodents)
- Variable (fragmentation)
- Disrupted architecture
- Increased wakefulness episodes
- Disrupts maintenance rather than onset
- Data compiled from rodent polysomnography studies using 10 mcg/kg subcutaneous BPC-157. Timing relative to circadian phase is the dominant predictor of sleep architecture disruption. Administration during late active phase produces the most pronounced sleep latency extension.